Bruker Corporation (BRKR) Receives Buy Rating from Jefferies Group LLC

Jefferies Group LLC reaffirmed their buy rating on shares of Bruker Corporation (NASDAQ:BRKR) in a research report released on Monday, May 15th, StockTargetPrices.com reports. They currently have a $29.00 target price on the medical research company’s stock.

A number of other analysts have also commented on the company. Deutsche Bank AG lifted their price target on Bruker Corporation from $25.00 to $27.00 and gave the company a hold rating in a research note on Monday, May 15th. Cowen and Company lifted their price target on Bruker Corporation from $25.00 to $27.00 and gave the company a market perform rating in a research note on Thursday, May 4th. Cleveland Research raised Bruker Corporation from a neutral rating to a buy rating in a research note on Thursday, April 27th. Janney Montgomery Scott downgraded Bruker Corporation from a buy rating to a neutral rating in a research report on Monday, March 27th. Finally, BTIG Research restated a hold rating on shares of Bruker Corporation in a research report on Wednesday, February 15th. Twelve analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $25.00.

Shares of Bruker Corporation (BRKR) traded down 0.14% during mid-day trading on Monday, reaching $27.71. The company’s stock had a trading volume of 880,321 shares. The company has a 50-day moving average of $26.54 and a 200-day moving average of $23.87. The firm has a market cap of $4.43 billion, a PE ratio of 29.42 and a beta of 1.02. Bruker Corporation has a 12 month low of $19.58 and a 12 month high of $28.35.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.19 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.19. Bruker Corporation had a return on equity of 26.88% and a net margin of 9.35%. The firm had revenue of $384.90 million for the quarter, compared to analyst estimates of $372.59 million. During the same period last year, the firm posted $0.21 earnings per share. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, analysts predict that Bruker Corporation will post $1.10 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Bruker Corporation (BRKR) Receives Buy Rating from Jefferies Group LLC” was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/06/16/bruker-co-brkr-stock-rating-reaffirmed-by-jefferies-group-llc-updated-updated-updated.html.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 23rd. Investors of record on Monday, June 5th will be given a dividend of $0.04 per share. The ex-dividend date is Thursday, June 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.58%. Bruker Corporation’s payout ratio is 17.02%.

In related news, CEO Frank H. Laukien bought 1,920 shares of the business’s stock in a transaction that occurred on Tuesday, May 16th. The shares were bought at an average price of $25.88 per share, with a total value of $49,689.60. Following the completion of the transaction, the chief executive officer now directly owns 37,712,851 shares in the company, valued at $976,008,583.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Frank H. Laukien bought 3,200 shares of the business’s stock in a transaction that occurred on Friday, May 19th. The shares were bought at an average cost of $26.13 per share, for a total transaction of $83,616.00. Following the transaction, the chief executive officer now owns 37,789,051 shares of the company’s stock, valued at $987,427,902.63. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 78,120 shares of company stock worth $2,047,366 and have sold 117,624 shares worth $3,271,574. 35.80% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Riverhead Capital Management LLC acquired a new position in Bruker Corporation during the third quarter valued at $136,000. Advisory Services Network LLC acquired a new position in Bruker Corporation during the first quarter valued at $150,000. Pacad Investment Ltd. boosted its position in Bruker Corporation by 100.0% in the fourth quarter. Pacad Investment Ltd. now owns 7,800 shares of the medical research company’s stock valued at $165,000 after buying an additional 3,900 shares in the last quarter. Capstone Asset Management Co. acquired a new position in Bruker Corporation during the first quarter valued at $203,000. Finally, Teacher Retirement System of Texas acquired a new position in Bruker Corporation during the first quarter valued at $209,000. 67.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker Corporation

Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. The Company’s segments include Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST).

Stock Target Prices

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply